Drug Profile
Research programme: cancer radiotherapeutics - Algeta
Alternative Names: 227Th conjugates; FGFR2-targeted thorium-227 conjugate; HER2-targeted thorium-227 conjugate; Targeted thorium conjugates - Algeta; TH-1 programme; thorium-227 conjugates; TTC - AlgetaLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Algeta
- Developer Algeta; Norwegian Radium Hospital
- Class Antibodies; Drug conjugates; Monoclonal antibodies; Peptides; Proteins; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Fibroblast growth factor receptor antagonists; Glutamate carboxypeptidase II inhibitors; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2023 NDR batch #29 - Retain the NDR as it is for preclinical development in Cancer in Norway (Parenteral, Injection) as company website is not accessible. And did not get nay info about it on free google search
- 28 Apr 2019 No recent reports of development identified for preclinical development in Cancer in Norway (Parenteral, Injection)
- 22 Mar 2017 Preclinical development is ongoing in Norway